<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6640652</article-id><article-id pub-id-type="doi">10.3389/fphar.2019.00746</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jia-jun</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn003">
<sup>&#x02020;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Yan-yan</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="author-notes" rid="fn003">
<sup>&#x02020;</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/573810"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Hong-mei</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="author-notes" rid="fn003">
<sup>&#x02020;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yun</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Chao-yue</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hu-biao</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jian-ye</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/534309"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup><institution>Guangdong Provincial Key Laboratory of Molecular Target &#x00026; Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff><aff id="aff2">
<sup>2</sup><institution>Institute of Respiratory and Occupational Diseases, Collaborative Innovation Center for Cancer, Medical College, Shanxi Datong University</institution>, <addr-line>Datong</addr-line>, <country>China</country></aff><aff id="aff3">
<sup>3</sup><institution>School of Chinese Medicine, Hong Kong Baptist University</institution>, <addr-line>Hong Kong</addr-line>, <country>China</country></aff><aff id="aff4">
<sup>4</sup><institution>Infinitus (China) Company Ltd.</institution>, <addr-line>Jiangmen</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Syed Nasir Abbas Bukhari, Al Jouf University, Saudi Arabia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Li Ye, Fudan University, China; Waqas Ahmad, University of Science Malaysia, Malaysia</p></fn><corresp id="fn001">*Correspondence: Jian-ye Zhang, <email xlink:href="mailto:jianyez@gzhmu.edu.cn" xlink:type="simple">jianyez@gzhmu.edu.cn</email>; Hubiao Chen, <email xlink:href="mailto:hbchen@hkbu.edu.hk" xlink:type="simple">hbchen@hkbu.edu.hk</email>
</corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p></fn><fn fn-type="equal" id="fn003"><p>&#x02020;These authors have contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>7</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>746</elocation-id><history><date date-type="received"><day>26</day><month>1</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Li, Yan, Sun, Liu, Su, Chen and Zhang</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Li, Yan, Sun, Liu, Su, Chen and Zhang</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>As a quinonemethide triterpenoid extracted from species of the <italic>Celastraceae</italic> and <italic>Hippocrateaceae</italic>, pristimerin has been shown potent anti-cancer effects. Specifically, it was found that pristimerin can affect many tumor-related processes, such as apoptosis, autophagy, migration and invasion, vasculogenesis, and drug resistance. Various molecular targets or signaling pathways are also involved, such as cyclins, reactive oxygen species (ROS), microRNA, nuclear factor kappa B (NF-&#x003ba;B), mitogen-activated protein kinase (MAPK), and PI3K/AKT/mammalian target of rapamycin (mTOR) pathways. In this review, we will focus on the research about pristimerin-induced anti-cancer activities to achieve a deeper understanding of the targets and mechanisms, which offer evidences suggesting that pristimerin can be a potent anti-cancer drug.</p></abstract><kwd-group><kwd>pristimerin</kwd><kwd>anti-cancer</kwd><kwd>mechanism</kwd><kwd>molecular target</kwd><kwd>pharmaceutical effect</kwd><kwd>apoptosis</kwd><kwd>autophagy</kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><equation-count count="0"/><ref-count count="98"/><page-count count="10"/><word-count count="4800"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>In recent years, natural compound has received more and more attention for use in treating human diseases and conditions, due to their long history of use and various pharmacological therapeutic effects (<xref rid="B72" ref-type="bibr">Tao et al., 2015</xref>; <xref rid="B95" ref-type="bibr">Zhang et al., 2015</xref>; <xref rid="B60" ref-type="bibr">Peng et al., 2016</xref>; <xref rid="B94" ref-type="bibr">Zhang et al., 2016</xref>; <xref rid="B41" ref-type="bibr">Lin et al., 2017</xref>), especially their relative safety (fewer and less severe side effects) than chemical drugs. Naturally occurring triterpenoid can be used as anti-cancer, anti-inflammatory, anti-malarial, and insecticidal agent (<xref rid="B12" ref-type="bibr">Deeb et al., 2012</xref>; <xref rid="B35" ref-type="bibr">Larsen et al., 2012</xref>; <xref rid="B31" ref-type="bibr">Kim et al., 2013</xref>; <xref rid="B11" ref-type="bibr">Deeb et al., 2014a</xref>). It has been proven that some natural or synthetic triterpenoids have promising clinical potential, exhibiting both therapeutic and chemopreventive activities for cancer (<xref rid="B64" ref-type="bibr">Salminen et al., 2008</xref>; <xref rid="B1" ref-type="bibr">Alessia et al., 2009</xref>; <xref rid="B30" ref-type="bibr">Ke et al., 2016</xref>). Pristimerin (20&#x003b1;-3-hydroxy-2-oxo-24-nor-friedela-1-10,3,5,7-tetraen-carboxylic acid-29-methylester, molecular formula: C<sub>30</sub>H<sub>40</sub>O<sub>4</sub>) (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>), a methyl ester of celastrol, is a quinonemethide triterpenoid which has been extracted from a variety of species of the <italic>Celastraceae</italic> and <italic>Hippocrateaceae</italic> families, such as <italic>Hippocratea excels</italic> (<xref rid="B50" ref-type="bibr">Mena-Rejon et al., 2007</xref>),<italic> Maytenus heterophylla</italic> (<xref rid="B55" ref-type="bibr">Murayama et al., 2007</xref>), and <italic>Celastrus aculeatus</italic> Merr. (<xref rid="B70" ref-type="bibr">Tang et al., 2014</xref>). Pristimerin was first isolated in 1951 from <italic>Pristimerae indica</italic> and <italic>P. grahami</italic> and was first identified in 1954 to confirm its molecular structure (<xref rid="B34" ref-type="bibr">Kulkarni and Shah, 1954</xref>). Pristimerin has displayed different pharmacological effects, such as anti-cancer, anti-oxidant, anti-inflammatory, anti-bacterial, anti-malarial, and insecticidal activities (<xref rid="B22" ref-type="bibr">Figueiredo and Sequin, 1998</xref>; <xref rid="B4" ref-type="bibr">Avilla et al., 2000</xref>; <xref rid="B26" ref-type="bibr">Haroldo Jeller et al., 2004</xref>; <xref rid="B46" ref-type="bibr">Lopez et al., 2011</xref>; <xref rid="B31" ref-type="bibr">Kim et al., 2013</xref>; <xref rid="B81" ref-type="bibr">Wu et al., 2019</xref>). As such, it is being developed as a potential anti-cancer drug (<xref rid="B93" ref-type="bibr">Yousef et al., 2017</xref>). Here, we present and discuss current research findings with regard to pristimerin emphasis on the anti-cancer effect.</p><fig id="f1" position="float"><label>Figure 1</label><caption><p>Chemical structure of pristimerin.</p></caption><graphic xlink:href="fphar-10-00746-g001"/></fig></sec><sec id="s2"><title>Pristimerin: Broad-Spectrum Anti-Cancer Effect</title><p>Cancer is a complicated disease, which starts with a normal change through the activation of proto-oncogenes or the suppression of tumor suppressor genes (<xref rid="B19" ref-type="bibr">Elmore, 2007</xref>). These alterations result in diversed and interactive changes at the level of cellular processes which are involved in the regulation of proliferation, differentiation, apoptosis, migration, and tissue homeostasis. Finally, biological properties for cancer cells are acquired, including infinite proliferation potential, independent exogenous growth factors, and resistance to death signals (<xref rid="B5" ref-type="bibr">Brattain et al., 1994</xref>; <xref rid="B15" ref-type="bibr">Dent and Aranda-Anzaldo, 2019</xref>; <xref rid="B61" ref-type="bibr">Petho et al., 2019</xref>; <xref rid="B66" ref-type="bibr">Shen et al., 2019</xref>).</p><p>Pristimerin exerts its effects influencing a series of biological properties of cancer cells. Recent studies on a wide range of cancer cell lines of different origins, such as oral cancer (<xref rid="B81" ref-type="bibr">Wu et al., 2019</xref>), colorectal cancer (<xref rid="B92" ref-type="bibr">Yousef et al., 2018</xref>), glioma (<xref rid="B88" ref-type="bibr">Yan et al., 2013</xref>), leukemia (<xref rid="B47" ref-type="bibr">Lu et al., 2010</xref>), breast cancer (<xref rid="B86" ref-type="bibr">Xie et al., 2016</xref>), lung cancer (<xref rid="B96" ref-type="bibr">Zhang et al., 2019</xref>), and prostate cancer (<xref rid="B42" ref-type="bibr">Liu et al., 2013</xref>), and also in cancer stem cells (<xref rid="B7" ref-type="bibr">Cevatemre et al., 2018</xref>). These results have proved that pristimerin possesses strong anti-proliferative activities with involvement of mitochondrial apoptosis, autophagy, and inhibition of nuclear factor kappa B (NF-&#x003ba;B), Akt (protein kinase B, PKB) and mitogen-activated protein kinase (MAPK) (<xref rid="B24" ref-type="bibr">Guo et al., 2013</xref>; <xref rid="B42" ref-type="bibr">Liu et al., 2013</xref>; <xref rid="B88" ref-type="bibr">Yan et al., 2013</xref>; <xref rid="B23" ref-type="bibr">Gao et al., 2014</xref>; <xref rid="B13" ref-type="bibr">Deeb et al., 2015</xref>).</p><p>In view of the potent anti-cancer effect in a broad spectrum (cancer cell lines and molecular targets), it possesses a great potential for pristimerin to develop as a multiple-target anti-cancer drug.</p></sec><sec id="s3"><title>Pristimerin: Anti-Cancer Activities</title><sec id="s3_1"><title>Growth Inhibition</title><p>Pristimerin induces a potent effect of growth inhibition within wide range types of human tumors; the cytotoxicity of pristimerin in different cancer cell lines is summarized in <xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The cytotoxicity dosage of pristimerin in different cancer cell lines</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="1" colspan="1">Cancer type</th><th valign="top" rowspan="1" colspan="1">Time</th><th valign="top" rowspan="1" colspan="1">Toxic dosage (IC<sub>50</sub> value or inhibition rate)</th><th valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" rowspan="2" colspan="1">Prostate cancer</td><td valign="top" rowspan="2" colspan="1">72&#x02009;h</td><td valign="top" rowspan="1" colspan="1">1.25&#x02009;&#x000b5;M caused 55% LNCaP cell death</td><td valign="top" rowspan="2" colspan="1">(<xref rid="B42" ref-type="bibr">Liu et al., 2013</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">1.25&#x02009;&#x000b5;M caused 47% PC-3 cell death</td></tr><tr><td valign="top" rowspan="1" colspan="1">Breast cancer</td><td valign="top" rowspan="1" colspan="1">24&#x02009;h</td><td valign="top" rowspan="1" colspan="1">2.40&#x02009;&#x000b5;M IC<sub>50</sub> against SKBR3</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B36" ref-type="bibr">Lee et al., 2013</xref>)</td></tr><tr><td valign="top" rowspan="4" colspan="1">Colorectal cancer</td><td valign="top" rowspan="1" colspan="1">72&#x02009;h</td><td valign="top" rowspan="1" colspan="1">1.11&#x02009;&#x000b5;M IC<sub>50</sub> against HCT-116</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B92" ref-type="bibr">Yousef et al., 2018</xref>)</td></tr><tr><td valign="top" rowspan="3" colspan="1">48&#x02009;h</td><td valign="top" rowspan="1" colspan="1">1.22&#x02009;&#x000b5;M IC<sub>50</sub> against HCT-116</td><td valign="top" rowspan="3" colspan="1">(<xref rid="B90" ref-type="bibr">Yousef et al., 2016a</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">1.04&#x02009;&#x000b5;M IC<sub>50</sub> against SW-620</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.84&#x02009;&#x000b5;M IC<sub>50</sub> against COLO-205</td></tr><tr><td valign="top" rowspan="4" colspan="1">Hepatocellular carcinoma</td><td valign="top" rowspan="4" colspan="1">72&#x02009;h</td><td valign="top" rowspan="1" colspan="1">1.44&#x02009;&#x000b5;M IC<sub>50</sub> against HepG2</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B24" ref-type="bibr">Guo et al., 2013</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">1.70&#x02009;&#x000b5;M IC<sub>50</sub> &#x000b5;M against HepG2</td><td valign="top" rowspan="3" colspan="1">(<xref rid="B80" ref-type="bibr">Wei et al., 2014</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.68&#x02009;&#x000b5;M IC<sub>50</sub> &#x000b5;M against Huh7</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.85&#x02009;&#x000b5;M IC<sub>50</sub> &#x000b5;M against Hep3B</td></tr><tr><td valign="top" rowspan="3" colspan="1">Pancreatic cancer</td><td valign="top" rowspan="1" colspan="1">24 h</td><td valign="top" rowspan="1" colspan="1">0.66&#x02009;&#x000b5;M, 0.97&#x02009;&#x000b5;M, 0.13&#x02009;&#x000b5;M, IC<sub>50</sub> against BxPC-3, PANC-1, and AsPC-1, respectively</td><td valign="top" rowspan="3" colspan="1">(<xref rid="B79" ref-type="bibr">Wang et al., 2012</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">48 h</td><td valign="top" rowspan="1" colspan="1">0.28&#x02009;&#x000b5;M, 0.34&#x02009;&#x000b5;M, and 0.38&#x02009;&#x000b5;M IC<sub>50</sub> against BxPC-3, PANC-1, and AsPC-1, respectively</td></tr><tr><td valign="top" rowspan="1" colspan="1">72 h</td><td valign="top" rowspan="1" colspan="1">0.19&#x02009;&#x000b5;M, 0.26&#x02009;&#x000b5;M and 0.30&#x02009;&#x000b5;M IC<sub>50</sub> against BxPC-3, PANC-1, and AsPC-1, respectively</td></tr><tr><td valign="top" rowspan="2" colspan="1">Glioma</td><td valign="top" rowspan="2" colspan="1">6 h</td><td valign="top" rowspan="1" colspan="1">4.5&#x02009;&#x000b5;M IC<sub>50</sub> against U251</td><td valign="top" rowspan="2" colspan="1">(<xref rid="B97" ref-type="bibr">Zhao et al., 2016</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">5.0&#x02009;&#x000b5;M IC<sub>50</sub> against U87</td></tr><tr><td valign="top" rowspan="5" colspan="1">Leukemia</td><td valign="top" rowspan="2" colspan="1">72 h</td><td valign="top" rowspan="1" colspan="1">0.61&#x02009;&#x000b5;M IC<sub>50</sub> against HL-60</td><td valign="top" rowspan="2" colspan="1">(<xref rid="B10" ref-type="bibr">Costa et al., 2008</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">1.49&#x02009;&#x000b5;M IC<sub>50</sub> against K562</td></tr><tr><td valign="top" rowspan="3" colspan="1">72 h</td><td valign="top" rowspan="1" colspan="1">199 nM IC<sub>50</sub> against KBM5</td><td valign="top" rowspan="3" colspan="1">(<xref rid="B47" ref-type="bibr">Lu et al., 2010</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">135 nM IC<sub>50</sub> against KBM5-T315I</td></tr><tr><td valign="top" rowspan="1" colspan="1">450 nM IC<sub>50</sub> against K562</td></tr><tr><td valign="top" rowspan="4" colspan="1">Ovarian carcinoma</td><td valign="top" rowspan="4" colspan="1">72 h</td><td valign="top" rowspan="1" colspan="1">1.25&#x02009;&#x000b5;M caused 44% OVCAR-5 cell death</td><td valign="top" rowspan="4" colspan="1">(<xref rid="B23" ref-type="bibr">Gao et al., 2014</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">1.25&#x02009;&#x000b5;M caused 28% MDAH-2774 cell death</td></tr><tr><td valign="top" rowspan="1" colspan="1">2.5&#x02009;&#x000b5;M caused 36% SK-OV-3 cell death</td></tr><tr><td valign="top" rowspan="1" colspan="1">2.5&#x02009;&#x000b5;M caused 27% OVCAR-3 cell death</td></tr><tr><td valign="top" rowspan="6" colspan="1">Osteosarcoma</td><td valign="top" rowspan="2" colspan="1">24 h</td><td valign="top" rowspan="1" colspan="1">0.80&#x02009;&#x000b5;M IC<sub>50</sub> against MNNG</td><td valign="top" rowspan="6" colspan="1">(<xref rid="B52" ref-type="bibr">Mori et al., 2017</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.54&#x02009;&#x000b5;M IC<sub>50</sub> against 143B</td></tr><tr><td valign="top" rowspan="2" colspan="1">48 h</td><td valign="top" rowspan="1" colspan="1">0.39&#x02009;&#x000b5;M IC<sub>50</sub> against MNNG</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.31&#x02009;&#x000b5;M IC<sub>50</sub> against 143B</td></tr><tr><td valign="top" rowspan="2" colspan="1">72 h</td><td valign="top" rowspan="1" colspan="1">0.32&#x02009;&#x000b5;M IC<sub>50</sub> against MNNG</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.29&#x02009;&#x000b5;M IC<sub>50</sub> against 143B</td></tr><tr><td valign="top" rowspan="4" colspan="1">Oral cancer</td><td valign="top" rowspan="4" colspan="1">72 h</td><td valign="top" rowspan="1" colspan="1">0.54&#x02009;&#x000b5;M IC<sub>50</sub> against KB</td><td valign="top" rowspan="2" colspan="1">(<xref rid="B87" ref-type="bibr">Yan et al., 2017</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.52&#x02009;&#x000b5;M IC<sub>50</sub> against KBv200</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.70&#x02009;&#x000b5;M IC<sub>50</sub> against CAL-27</td><td valign="top" rowspan="2" colspan="1">(<xref rid="B81" ref-type="bibr">Wu et al., 2019</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">0.73&#x02009;&#x000b5;M IC<sub>50</sub> against SCC-25</td></tr><tr><td valign="top" rowspan="3" colspan="1">ESCC</td><td valign="top" rowspan="3" colspan="1">72 h</td><td valign="top" rowspan="1" colspan="1">1.98&#x02009;&#x000b5;M IC<sub>50</sub> against EC9706</td><td valign="top" rowspan="3" colspan="1">(<xref rid="B74" ref-type="bibr">Tu et al., 2018</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">1.76&#x02009;&#x000b5;M IC<sub>50</sub> against EC109</td></tr><tr><td valign="top" rowspan="1" colspan="1">1.13&#x02009;&#x000b5;M IC<sub>50</sub> against KYSE30</td></tr></tbody></table><table-wrap-foot><p>ESCC, esophageal squamous cell carcinoma.</p></table-wrap-foot></table-wrap></sec><sec id="s3_2"><title>Apoptosis Induction</title><p>Apoptosis is a kind of programmed cell death, whose activation is regulated by a series of genes, in the purpose of eliminating redundant, damaged, even infected cells to maintain homeostasis (<xref rid="B30" ref-type="bibr">Ke et al., 2016</xref>). Anti-cancer agents killing tumor cells by the induction of apoptosis is generally studied (<xref rid="B83" ref-type="bibr">Wu et al., 2017</xref>; <xref rid="B85" ref-type="bibr">Xiao et al., 2018</xref>; <xref rid="B62" ref-type="bibr">Qi et al., 2019</xref>). Two main subtypes of apoptosis have been divided into the intrinsic mitochondrial pathway and the extrinsic death receptor pathway (<xref rid="B19" ref-type="bibr">Elmore, 2007</xref>).</p><p>In the mitochondrial pathway, Bcl-2 family members converge on mitochondria (<xref rid="B29" ref-type="bibr">Kale et al., 2018</xref>), regulating release of various mitochondrial components to form the apoptosome (<xref rid="B17" ref-type="bibr">Dorstyn et al., 2018</xref>), such as cytochrome <italic>c</italic> associated with Apaf-1 and procaspase-9 (<xref rid="B20" ref-type="bibr">Estaquier et al., 2012</xref>). In the death receptor pathway, stimulation of death receptors, including Fas and tumor necrosis factor (TNF) receptor-1, results in the assembly of death-inducing signaling complex, containing the adapter protein (<xref rid="B25" ref-type="bibr">Gupta, 2001</xref>), Fas-associated death domain, and initiator caspases, such as caspase-8 (<xref rid="B58" ref-type="bibr">Pecina-Slaus, 2009</xref>).</p><p>Pristimerin-induced apoptotic effects were mainly due to mitochondrial dysfunction, activation of both extrinsic and intrinsic caspases, and cleavage of poly ADP-ribose polymerase (PARP). It has been reported that pristimerin can induce caspase-dependent apoptosis in human glioma cancer cells (<xref rid="B88" ref-type="bibr">Yan et al., 2013</xref>), pancreatic cancer cells (<xref rid="B14" ref-type="bibr">Deeb et al., 2014b</xref>), and hepatoma cancer cells (<xref rid="B23" ref-type="bibr">Gao et al., 2014</xref>). Pristimerin-induced inhibition of Bcl-2 (as well as Bcl-2 mRNA) is sufficient to promote mitochondrial permeability transition and release of cytochrome <italic>c</italic> mediated by Bax and Bak without the inhibition of Bcl-xL in pancreatic cancer cells (<xref rid="B14" ref-type="bibr">Deeb et al., 2014b</xref>). On the other hand, caspase inhibitor failed to antagonize the effects of pristimerin, indicating that the lethal effect of pristimerin may not be caspase-dependent in human glioma U251 and U87 cells (<xref rid="B97" ref-type="bibr">Zhao et al., 2016</xref>).</p><p>The apoptotic effect of pristimerin is related to Bcl-2, and it mediates down-regulation of Bcl-2 through reactive oxygen species (ROS)-dependent ubiquitin-proteasomal degradation pathway in human prostate cancer LNCaP and PC-3 cells (<xref rid="B42" ref-type="bibr">Liu et al., 2013</xref>). ROS-induced apoptosis by pritimerin was also reported in hepatocellular carcinoma HepG2 cells, involving EGFR and Akt proteins (<xref rid="B24" ref-type="bibr">Guo et al., 2013</xref>). In colorectal carcinoma cells, the associated induction of JNK activation and MMP loss was observed (<xref rid="B91" ref-type="bibr">Yousef et al., 2016b</xref>), similar with the results in cervical cancer cells (<xref rid="B6" ref-type="bibr">Byun et al., 2009</xref>).</p><p>In human colon cancer cells, pristimerin caused cell cycle arrest and apoptosis through cyclin-CDK, mitochondrial dysfunction, and caspase-dependent mechanisms. Besides, the inhibition of DNA synthesis in HL-60 was also associated with pristimerin-induced apoptosis (<xref rid="B10" ref-type="bibr">Costa et al., 2008</xref>).</p><p>Pristimerin-induced apoptosis could be mediated by microRNA (miRNA). miRNAs exert a post-transcriptional gene silencing effect through binding to target mRNA and endonucleolytic cleavage of the mRNA by protein argonaute-2 (AGO2) (<xref rid="B32" ref-type="bibr">Kobayashi and Tomari, 2016</xref>). It was reported that pristimerin induced apoptosis through inhibiting AGO2 and PTPN1 expression <italic>via</italic> miR-542-5p in glioma cancer cells U373 (<xref rid="B40" ref-type="bibr">Li et al., 2019</xref>). Synergization with cisplatin, pristimerin led to apoptosis <italic>via</italic> inhibiting the miR-23a, regulating PTEN/Akt signaling-related PTEN and the phosphorylation of Akt and GSK3&#x003b2; in lung carcinoma NCI-H446 and A549 cells (<xref rid="B96" ref-type="bibr">Zhang et al., 2019</xref>).</p></sec><sec id="s3_3"><title>Autophagy Induction</title><p>As another programmed necrosis, autophagy is a homeostatic cellular self-digestive process. Autophagy triggered by various cellular stress plays vital role in cell death, providing novel target for developing anti-cancer drug (<xref rid="B51" ref-type="bibr">Mizushima et al., 2008</xref>; <xref rid="B63" ref-type="bibr">Ravanan et al., 2017</xref>). LC3-II promotes the expansion and maturation of autophagy, which is considered as signal of autophagy activation. Pristimerin-induced autophagy was reported in human breast cancer MDA-MB-231 (<xref rid="B7" ref-type="bibr">Cevatemre et al., 2018</xref>; <xref rid="B38" ref-type="bibr">Lee et al., 2018</xref>) and MCF-7 cells (<xref rid="B7" ref-type="bibr">Cevatemre et al., 2018</xref>). As evidenced by the increase of p62 and LC3-II with an unfolded protein response (UPR), pristimerin induced an incompleted autophagy through Wnt signaling. Although endoplasmic reticulum (ER) stress is also a trigger of autophagy (<xref rid="B67" ref-type="bibr">Smith and Wilkinson, 2017</xref>), it was not concluded whether the observed ER stress by pristimerin induced autophagy (<xref rid="B7" ref-type="bibr">Cevatemre et al., 2018</xref>). Additionally, a combination treatment of pristimerin and paclitaxel strengthened the extracellular signal-related kinase (ERK)-dependent autophagic cell death, with increase of p62 degradation and beclin1 expression (<xref rid="B38" ref-type="bibr">Lee et al., 2018</xref>).</p><p>On the contrary, pristimerin suppressed autophagy, downregulating LC3BII and beclin1 to sensitize the apoptosis caused by cisplatin in lung carcinoma A549 and NCI-H446 cells (<xref rid="B96" ref-type="bibr">Zhang et al., 2019</xref>).</p></sec><sec id="s3_4"><title>Inhibition of Metastasis, Migration, Invasion, Angiogensis, and Cancer Stem Cell</title><p>The cancer metastases include a series of process, such as the completion of a complex succession of cell-biological event, cancer cell invasion, migration, and forming metastatic colonization in clinic (<xref rid="B75" ref-type="bibr">Valastyan and Weinberg, 2011</xref>). Pristimerin was reported to inhibit migration and invasion <italic>via</italic> targeting G protein signaling 4 (RGS4) in breast cancer MDA-MB-231 cells (<xref rid="B53" ref-type="bibr">Mu et al., 2012a</xref>) and HER2 in human breast carcinoma SKBR3 cells (<xref rid="B36" ref-type="bibr">Lee et al., 2013</xref>). Furthermore, mammalian target of rapamycin (mTOR) may be associated with its upstream Akt in pristimerin-induced inhibition of migration and invasion in colorectal cancer HCT-116 cells (<xref rid="B91" ref-type="bibr">Yousef et al., 2016b</xref>). Pristimerin suppressed the invasion of human prostate cancer PC-3 cells through inhibition of epithelial-to-mesenchymal transition (EMT), which was confirmed by the EMT-related markers (<xref rid="B8" ref-type="bibr">Chaffer et al., 2016</xref>), including N-cadherin, fibronectin, vimentin and ZEB1 (<xref rid="B98" ref-type="bibr">Zuo et al., 2015</xref>). MMP2 and MMP9, which are important proteins regulating invasion and metastasis, were decreased by pristimerin in esophageal cancer EC9706 and EC109 cells in a dose-dependent manner, resulting in inhibition of migration and invasion (<xref rid="B74" ref-type="bibr">Tu et al., 2018</xref>).</p><p>To supply nutrients and clear metabolic wastes, novel capillary blood vessels grow from pre-existing vasculature, which is called angiogenesis. However, aberrant angiogenesis plays a key role in cancer development (<xref rid="B75" ref-type="bibr">Valastyan and Weinberg, 2011</xref>). Thus, anti-angiogenic therapy is promising and under development (<xref rid="B39" ref-type="bibr">Li et al., 2018</xref>). Pristimerin was reported to <italic>in vivo</italic> inhibit the neovascularization of chicken chorioallantoic membrane (CAM) and vessel <italic>ex vivo</italic> sprout in rat aortic ring assay, through a vascular endothelial growth factor (VEGF)-dependent mechanism (<xref rid="B54" ref-type="bibr">Mu et al., 2012b</xref>). Also, the decreased-VEGF by pristimerin was reported through the inhibition of HIF-1&#x003b1; <italic>via</italic> the SPHK-1 signaling pathway in hypoxic prostate cancer PC-3 cells (<xref rid="B37" ref-type="bibr">Lee et al., 2016</xref>). In addition, pristimerin-induced cancer stem cell toxicity was observed in breast cancer stem cells (<xref rid="B7" ref-type="bibr">Cevatemre et al., 2018</xref>) and esophageal squamous cell carcinoma (ESCC) (<xref rid="B74" ref-type="bibr">Tu et al., 2018</xref>).</p></sec><sec id="s3_5"><title>Reversal of Drug Resistance</title><p>Multi-drug resistance (MDR) is defined as the resistance of cancer cells not limited to a specific chemotherapeutic drug through different structures and mechanisms of action (<xref rid="B82" ref-type="bibr">Wu et al., 2014</xref>). ABCB1 (P-glycoprotein, Pgp) is recognized as putative drug transporter, which is encoded by the ABCB1 gene, one of (ATP)-binding cassette (ABC) transporter family (<xref rid="B16" ref-type="bibr">Dewanjee et al., 2017</xref>). Pristimerin may overcome ABCB1-mediated chemotherapeutic drug resistance through disturbing the stability of ABCB1 independent of its mRNA expression in human oral epidermoid carcinoma cells KBv200 (<xref rid="B87" ref-type="bibr">Yan et al., 2017</xref>). In addition, with inhibition of NF-&#x003ba;B and Bcr-Abl, pristimerin is effective <italic>in vitro</italic> and <italic>in vivo</italic> against imatinib-resistant chronic myelogenous leukemia cells (<xref rid="B47" ref-type="bibr">Lu et al., 2010</xref>). Additionally, Akt signaling was related to the reversal of MDR in multidrug-resistant MCF-7/ADR breast cancer cells (<xref rid="B86" ref-type="bibr">Xie et al., 2016</xref>).</p></sec><sec id="s3_6"><title>Synergization With Chemotherapeutic Drugs</title><p>Drug combination for cancer treatment has been well established to strengthen the anti-tumor action in varied aspects (<xref rid="B27" ref-type="bibr">Ho and Cheung, 2014</xref>; <xref rid="B2" ref-type="bibr">Andre et al., 2018</xref>), including therapeutic drug combination with natural product (<xref rid="B18" ref-type="bibr">Efferth, 2017</xref>; <xref rid="B65" ref-type="bibr">Sanchez et al., 2019</xref>). Pristimerin was reported to synergize with paclitaxel in human breast cancer cells (<xref rid="B38" ref-type="bibr">Lee et al., 2018</xref>), with 5-fluorouracil (5-FU) in esophageal ESCC (<xref rid="B74" ref-type="bibr">Tu et al., 2018</xref>). In cervical cancer cells, combination with taxol could induce cell death through ROS-mediated mitochondrial dysfunction (<xref rid="B21" ref-type="bibr">Eum et al., 2011</xref>). In NCI-H446 and A549 lung carcinoma cells, combination with cisplatin could induce cell apoptosis through inhibiting the miRNA-23a and Akt/GSK3&#x003b2; signaling pathway (<xref rid="B96" ref-type="bibr">Zhang et al., 2019</xref>). In pancreatic cancer cells, pristimerin could potentiate the cytotoxic effect of gemcitabine with the possible mechanism being the inhibition of gemcitabine-induced NF-&#x003ba;B activation (<xref rid="B79" ref-type="bibr">Wang et al., 2012</xref>).</p></sec><sec id="s3_7"><title>
<italic>In Vivo</italic> Anti-Tumor Activities</title><p>Pristimerin was widely reported its <italic>in vivo</italic> anti-tumor activities, which is summarized in <xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>
<italic>In vivo</italic> anti-tumor activities of pristimerin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="1" colspan="1">Models</th><th valign="top" rowspan="1" colspan="1">Dose and administration</th><th valign="top" rowspan="1" colspan="1">Activities</th><th valign="top" rowspan="1" colspan="1">Mechanisms</th><th valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">Human breast tumor xenograft model</td><td valign="top" rowspan="1" colspan="1">3&#x02009;mg/kg/2 days, s.c.</td><td valign="top" rowspan="1" colspan="1">Reduced both tumor volume and tumor weight, inhibited tumor angiogenesis.</td><td valign="top" rowspan="1" colspan="1">Associated with decreased secretion of proangiogenic molecules (VEGF)</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B54" ref-type="bibr">Mu et al., 2012b</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human breast tumor xenograft model</td><td valign="top" rowspan="1" colspan="1">1&#x02009;mg/kg/2 days, s.c.</td><td valign="top" rowspan="1" colspan="1">Inhibited the growth of implanted tumors, inhibited the invasiveness</td><td valign="top" rowspan="1" colspan="1">&#x02014;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">Mu et al., 2012a</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Orthotopic HCC patient-derived xenograft model</td><td valign="top" rowspan="1" colspan="1">1&#x02009;mg/kg/3 times/week, i.v.</td><td valign="top" rowspan="1" colspan="1">Caused significant reductions in tumor volumes of xenografts</td><td valign="top" rowspan="1" colspan="1">Disrupt HSP90 and CDC37 interaction, inhibit Raf/MEK/ERK and PI3K/AKT/mTOR pathways</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B80" ref-type="bibr">Wei et al., 2014</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Intra-tibial injection model</td><td valign="top" rowspan="1" colspan="1">7.5 &#x000d7; 10<sup>3</sup> cells/&#x000b5;l 1.6&#x02009;&#x000b5;M pristimerin pre-treated 24&#x02009;h PC-3 cells</td><td valign="top" rowspan="1" colspan="1">Inhibited the bone destruction by the invasion of the tumor, reduced the tumorigenic potential of bone metastasis</td><td valign="top" rowspan="1" colspan="1">&#x02014;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">Huang et al., 2015</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human glioma xenograft model</td><td valign="top" rowspan="1" colspan="1">1 and 3&#x02009;mg/kg/2 days, s.c.</td><td valign="top" rowspan="1" colspan="1">Inhibited glioma volume and weight <italic>in vivo</italic> in a dose-dependent manner</td><td valign="top" rowspan="1" colspan="1">Up-regulated JNK level the phosphorylated JNK, upregulated the nuclear AIF and the ratio of Bax/Bcl-2</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B97" ref-type="bibr">Zhao et al., 2016</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">AOM/DSS model of colitis-associated colorectal carcinogenesis</td><td valign="top" rowspan="1" colspan="1">fed with 1 to 5 ppm pristimerin</td><td valign="top" rowspan="1" colspan="1">Reduced tumor burden</td><td valign="top" rowspan="1" colspan="1">&#x02014;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B57" ref-type="bibr">Park and Kim, 2018</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human ESCC xenograft model</td><td valign="top" rowspan="1" colspan="1">1&#x02009;mg/kg/2 days, i.t.</td><td valign="top" rowspan="1" colspan="1">Inhibited the growth and weight of tumor, suppressed proliferation</td><td valign="top" rowspan="1" colspan="1">&#x02014;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B74" ref-type="bibr">Tu et al., 2018</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human colorectal cancer xenograft model</td><td valign="top" rowspan="1" colspan="1">1&#x02009;mg/kg/2 days, i.p.</td><td valign="top" rowspan="1" colspan="1">Inhibited tumor growth</td><td valign="top" rowspan="1" colspan="1">Mainly through suppressing NF-&#x0043a;B activity and p65 phosphorylation</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B92" ref-type="bibr">Yousef et al., 2018</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human lung tumors xenograft model</td><td valign="top" rowspan="1" colspan="1">0.8&#x02009;mg/kg pristimerin and 2&#x02009;mg/kg cisplatin, s.c.</td><td valign="top" rowspan="1" colspan="1">Enhanced the effect of cisplatin to decrease tumor volumes and weights</td><td valign="top" rowspan="1" colspan="1">Inhibited the phosphorylation of Akt and GSK3&#x003b2;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B96" ref-type="bibr">Zhang et al., 2019</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human osteosarcoma xenograft model</td><td valign="top" rowspan="1" colspan="1">1&#x02009;mg/kg/2 days, i.p.</td><td valign="top" rowspan="1" colspan="1">Reduced both tumor volume and tumor weight</td><td valign="top" rowspan="1" colspan="1">&#x02014;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B52" ref-type="bibr">Mori et al., 2017</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human colorectal cancer xenograft model</td><td valign="top" rowspan="1" colspan="1">1&#x02009;mg/kg/2 days, i.p.</td><td valign="top" rowspan="1" colspan="1">Inhibited the growth of<break/>implanted tumors</td><td valign="top" rowspan="1" colspan="1">Induced apoptosis through an increment in cleaved caspase-3</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B91" ref-type="bibr">Yousef et al., 2016b</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human myeloma xenograft model</td><td valign="top" rowspan="1" colspan="1">2.5&#x02009;mg/kg per day, s.c.</td><td valign="top" rowspan="1" colspan="1">Inhibited growth of human myeloma xenograft, diminished toxicity in a liposomal dose</td><td valign="top" rowspan="1" colspan="1">&#x02014;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">Tiedemann et al., 2009</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Human breast cancer xenograft model</td><td valign="top" rowspan="1" colspan="1">1&#x02009;mg/kg for 2 days, i.p.</td><td valign="top" rowspan="1" colspan="1">Decreased tumor size and weights, slightly reduced toxicity and behavioral changes in an E/T80/WFI carrier compared to D/PBS.</td><td valign="top" rowspan="1" colspan="1">&#x02014;</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B7" ref-type="bibr">Cevatemre et al., 2018</xref>)</td></tr></tbody></table><table-wrap-foot><p>*s.c. represents subcutaneously, i.v. for intravenously, i.t. for intratumorly, i.p. for intraperitoneally, and ppm for parts per million, respectively. ERK, extracellular signal-related kinase.</p></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Pristimerin in Tumors: Targets and Pathways</title><sec id="s4_1"><title>Proteasome</title><p>As another important mechanism of maintaining homeostasis, proteasome-mediated degradation is associated with essential cellular processes, regulating the vast majority of cellular proteins (<xref rid="B45" ref-type="bibr">Livneh et al., 2016</xref>). Consistent with triterpenoids being reported to target proteasome (<xref rid="B9" ref-type="bibr">Chintharlapalli et al., 2007</xref>; <xref rid="B73" ref-type="bibr">Tiedemann et al., 2009</xref>), pristimerin also showed a potent activity to inhibit proteasome activity in prostate cancer cells (<xref rid="B89" ref-type="bibr">Yang et al., 2010</xref>; <xref rid="B42" ref-type="bibr">Liu et al., 2013</xref>; <xref rid="B43" ref-type="bibr">Liu et al., 2014</xref>), breast cancer cells (<xref rid="B53" ref-type="bibr">Mu et al., 2012a</xref>), cervical carcinoma cells (<xref rid="B21" ref-type="bibr">Eum et al., 2011</xref>), and myeloma cells (<xref rid="B73" ref-type="bibr">Tiedemann et al., 2009</xref>).</p><p>The &#x003b2; subunits of proteasome contain active protease sites with different peptidase activities, including caspase-like or peptidyl-glutamyl peptide-hydrolyzing-like (&#x003b2;1), trypsin-like post basic (&#x003b2;2), and chymotrypsin-like (&#x003b2;5) activities (<xref rid="B49" ref-type="bibr">Mayor et al., 2016</xref>). Pristimerin was associated with the N-terminal threonine of the &#x003b2;5 subunit through its conjugated ketone carbon C<sub>6</sub>, exerting a chymotrypsin-like activity (<xref rid="B89" ref-type="bibr">Yang et al., 2010</xref>), which is also associated with RGS4 (<xref rid="B53" ref-type="bibr">Mu et al., 2012a</xref>).</p><p>Pristimerin can inhibit Bcl-2, finally induced mitochondrial cell death <italic>via</italic> an ROS-dependent ubiquitin-proteasomal degradation pathway (<xref rid="B42" ref-type="bibr">Liu et al., 2013</xref>). Pristimerin combination with taxol caused mitochondrial apoptosis due to ROS generation and direct proteasome inhibition (<xref rid="B21" ref-type="bibr">Eum et al., 2011</xref>). In addition, pristimerin-induced inhibition of proteosome and IKK phosphorylation of I&#x003ba;B together led to UPR and suppression of NF-&#x003ba;B activity and cyclin D2 expression in myeloma cells H929 and U266 (<xref rid="B73" ref-type="bibr">Tiedemann et al., 2009</xref>).</p></sec><sec id="s4_2"><title>Telomerase</title><p>Telomere is a ribonucleoprotein complex located in the end of chromosomes, maintaining telomere length homeostasis to keep chromosomal stability (<xref rid="B78" ref-type="bibr">Wang and Feigon, 2017</xref>). Due to the differences in telomere homeostasis between cancer and normal cells, targeting telomerase may be a promising approach to find effective and safe anti-cancer treatments (<xref rid="B3" ref-type="bibr">Armstrong and Tomita, 2017</xref>).</p><p>Pristimerin can inhibit telomerase activity in human prostate cancer LNCaP and PC-3 cells (<xref rid="B44" ref-type="bibr">Liu et al., 2015</xref>). The mechanism is related to inhibition of human telomerase reverse transcriptase (hTERT) and its mRNA expression, which codes the catalytic subunit of the telomerase. At the same time, knocking-down of hTERT strengthened the effects of pristimerin. Furthermore, hTERT regulatory proteins c-Myc, Sp1, p-STAT3, and p-Akt were inhibited in a dose-dependent manner (<xref rid="B44" ref-type="bibr">Liu et al., 2015</xref>).</p></sec><sec id="s4_3"><title>MAPK Pathway</title><p>The generic MAPK signaling pathway is co-regulated by four different cascades including extracellular signal-related kinases (ERK1/2), Jun amino-terminal kinases (JNK1/2/3), p38-MAPK, and ERK5 (<xref rid="B69" ref-type="bibr">Sun et al., 2015</xref>). MAPK/ERK pathway regulates the cell proliferation (<xref rid="B68" ref-type="bibr">Sun et al., 2017</xref>), differentiation (<xref rid="B76" ref-type="bibr">Wang et al., 2017</xref>), migration (<xref rid="B71" ref-type="bibr">Tao et al., 2018</xref>) and apoptosis (<xref rid="B77" ref-type="bibr">Wang and Zhu, 2018</xref>).</p><p>Pristimerin-induced autophagy was reported <italic>via</italic> ERK1/2 in human breast cancer cells when combination with paclitaxel (<xref rid="B38" ref-type="bibr">Lee et al., 2018</xref>). ERK1/2 may be involved in pristimerin-induced intrinsic apoptosis in human oral epidermoid carcinoma cells (<xref rid="B87" ref-type="bibr">Yan et al., 2017</xref>) and in human glioma cells (<xref rid="B88" ref-type="bibr">Yan et al., 2013</xref>). Both JNK and PARP-1 <italic>via</italic> ROS pathway are essentially required for the pristimerin-induced intrinsic apoptosis in human cervical cancer cells (<xref rid="B6" ref-type="bibr">Byun et al., 2009</xref>). In addition, ERK1/2 suppression occurred in VEGF-induced capillary-like structure formation of human umbilical vascular endothelial cells (HUVECs) (<xref rid="B54" ref-type="bibr">Mu et al., 2012b</xref>). These activities were accompanied with Akt inhibition (<xref rid="B54" ref-type="bibr">Mu et al., 2012b</xref>; <xref rid="B87" ref-type="bibr">Yan et al., 2017</xref>; <xref rid="B38" ref-type="bibr">Lee et al., 2018</xref>).</p></sec><sec id="s4_4"><title>PI3K/AKT/mTOR Pathway</title><p>The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway cascade containing PI3K, AKT, and mTOR is the most frequently altered pathway in human for cancer development, such as cell cycle, cell survival, metabolism, motility, angiogenesis, chemoresistance, and genomic instability (<xref rid="B48" ref-type="bibr">Mabuchi et al., 2015</xref>).</p><p>Pristimerin showed a potent apoptosis-inducing anti-proliferative activity in human osteosarcoma cells (<xref rid="B52" ref-type="bibr">Mori et al., 2017</xref>) by PI3K/AKT/mTOR pathway. The pristimerin-induced ROS-dependent mitochondrial cell apoptosis was also associated with the inhibition of EGFR and Akt in human glioma cells (<xref rid="B88" ref-type="bibr">Yan et al., 2013</xref>). It was confirmed that PI3K/AKT/mTOR pathway-activated activities were accompanied by the downstream Foxo-3&#x003b1;, cyclin D1 and Bcl-XL (Akt), p-S6K1, and p-4E-BP1 (mTOR) as well as p21, p27, and PKC&#x003b5; in human ovarian cancer cells (<xref rid="B14" ref-type="bibr">Deeb et al., 2014b</xref>; <xref rid="B23" ref-type="bibr">Gao et al., 2014</xref>; <xref rid="B57" ref-type="bibr">Park and Kim, 2018</xref>). Furthermore, downstream Bad and Bcl-xL pointed to drug resistance in MCF-7/ADR human breast cancer cells (<xref rid="B86" ref-type="bibr">Xie et al., 2016</xref>). In addition, pristimerin suppressed angiogenesis through VEGF-induced Akt, ERK1/2, mTOR, and ribosomal protein S6 kinase (<xref rid="B54" ref-type="bibr">Mu et al., 2012b</xref>).</p></sec><sec id="s4_5"><title>NF-&#x003ba;B Pathway</title><p>NF-&#x003ba;B family transcription factors are crucial regulators of cell survival and inflammatory processes (<xref rid="B56" ref-type="bibr">Napetschnig and Wu, 2013</xref>). The inactive NF-&#x003ba;Bs are isolated from nucleus by inhibitor of NF-&#x003ba;B (I&#x003ba;B) proteins. When activated IKK (I&#x003ba;B kinase) makes a proteasomal degradation of I&#x003ba;B, the subsequent process will occur, including the release of NF-&#x003ba;B, translocation of NF-&#x003ba;B nuclear and activation of gene transcription. NF-&#x003ba;B can be activated by both intracellular and extracellular stimuli, including cytokines (TNF-&#x003b1;, IL-1&#x003b2;), bacterial, and viral products (LPS) (<xref rid="B84" ref-type="bibr">Xia et al., 2014</xref>).</p><p>NF-&#x003ba;B-regulated anti-apoptotic Bcl-2, Bcl-xL, c-IAPl, and surviving in human ovarian carcinoma cells (<xref rid="B23" ref-type="bibr">Gao et al., 2014</xref>), Cox-2 and VEGF in human pancreatic cancer cells (<xref rid="B14" ref-type="bibr">Deeb et al., 2014b</xref>). NF-&#x003ba;B pathway may link anti-tumor activity of pristimerin and its anti-inflammatory properties (<xref rid="B57" ref-type="bibr">Park and Kim, 2018</xref>). Pristimerin suppressed the translocation of NF-&#x003ba;B nuclear; however, there was no change of the total NF-&#x003ba;B protein in pancreatic cancer (<xref rid="B79" ref-type="bibr">Wang et al., 2012</xref>). In contrast, pristimerin inhibited both genetic expression and activation of NF-&#x0043a;B protein with suppression of p65 mRNA in human colorectal cancer cells (<xref rid="B92" ref-type="bibr">Yousef et al., 2018</xref>). TNF&#x003b1;-induced NF-&#x003ba;B activation was observed by the downstream MMP9, cyclin D1, and c-Myc in ESCC cells (<xref rid="B74" ref-type="bibr">Tu et al., 2018</xref>). When combined with pristimerin, the inactivation of Bcr-Abl by imatinib did not interfere with the TNF&#x003b1;-induced NF-&#x003ba;B activation, which implicated that NF-&#x003ba;B inactivation and Bcr-Abl inhibition may be parallel mechanisms of pristimerin-induced activity in human chronic myelogenous leukemia cells (<xref rid="B47" ref-type="bibr">Lu et al., 2010</xref>). G1 phase arrest was also associated with NF-&#x003ba;B pathway in human pancreatic cancer cells (<xref rid="B79" ref-type="bibr">Wang et al., 2012</xref>), as well as proteosome in human myeloma cells (<xref rid="B73" ref-type="bibr">Tiedemann et al., 2009</xref>). Moreover, pristimerin inhibited expression of miR-542-5p targeting PTPN1, which encodes protein tyrosine phosphatase 1B (PTP1B) related to NF-&#x003ba;B pathway (<xref rid="B40" ref-type="bibr">Li et al., 2019</xref>).</p></sec><sec id="s4_6"><title>Wnt/&#x003b2;-Catenin Pathway</title><p>Wnt proteins are key mediators in a series of important cellular process. The abnormal activation of Wnt/&#x003b2;-catenin pathway can cause a wide range of diseases including cancers (<xref rid="B33" ref-type="bibr">Krishnamurthy and Kurzrock, 2018</xref>; <xref rid="B59" ref-type="bibr">Pedone and Marucci, 2019</xref>). Pristimerin was reported to suppress Wnt/&#x003b2;-catenin pathway through targeting and inhibiting the expression of LRP6 and its phosphorylation, which may contribute to autophagy in human breast cancer MCF-7 cells (<xref rid="B7" ref-type="bibr">Cevatemre et al., 2018</xref>).</p></sec></sec><sec sec-type="conclusions" id="s5"><title>Conclusions and Perspective</title><p>Plants, particularly medicinal herbs, have become increasingly popular due to their potent therapeutic effects. Pristimerin, a quininemethide triterpenoid compound isolated from species of the <italic>Celastraceae</italic> and <italic>Hippocrateaceae</italic> families, has displayed biological and pharmacological activities, particularly inhibiting cancer. This review summarizes the reported results on anti-cancer activities and related mechanisms of pristimerin.</p><p>Pristimerin has shown anti-cancer potency <italic>in vivo</italic> (<xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref>) and <italic>in vitro</italic> (<xref rid="T3" ref-type="table">
<bold>Table 3</bold>
</xref>) <italic>via</italic> specific mechanisms (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>). Like many other chemotherapeutic drugs, pristimerin exerts cytotoxicity largely related to apoptosis, while the mechanism of autophagy is merely reported. The cross-talk of apoptosis and autophagy mediated by pristimerin is still remained to be explored. So far, the mechanism study of pristimerin has little reported on lung cancer, epigenetic regulation, and combination with immunotherapy. Furthermore, pristimerin has been reported to have poor selective toxicity in some cancer cells or compared with its derivatives (<xref rid="B10" ref-type="bibr">Costa et al., 2008</xref>; <xref rid="B80" ref-type="bibr">Wei et al., 2014</xref>). Comprehensive evaluation of pristimerin toxicity is yet to be carried out (as well as clinical trials). In summary, pristimerin possesses potent anti-cancer effect and further study will bring about novel drug development based on pristimerin.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Anti-cancer mechanisms of pristimerin in different cell lines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="1" colspan="1">Cancer type</th><th valign="top" rowspan="1" colspan="1">Cell lines</th><th valign="top" rowspan="1" colspan="1">Mechanisms</th><th valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" rowspan="5" colspan="1">Prostate cancer</td><td valign="top" rowspan="2" colspan="1">PC-3</td><td valign="top" rowspan="1" colspan="1">Inhibited HIF-1&#x003b1; accumulation by inhibiting SPHK-1</td><td valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" rowspan="1" colspan="1">Inhibited CD133 and CD44 protein expression, reduced VEGF</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">Huang et al., 2015</xref>)</td></tr><tr><td valign="top" rowspan="3" colspan="1">LNCaP and PC-3</td><td valign="top" rowspan="1" colspan="1">Down-regulated Bcl-2 through an ROS-dependent ubiquitin-proteasomal degradation pathway</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B42" ref-type="bibr">Liu et al., 2013</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Prevented survivin <italic>via</italic> the ubiquitin-proteasome pathway</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B43" ref-type="bibr">Liu et al., 2014</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Inhibited hTERT expression <italic>via</italic> the inhibition of SP1, c-Myc, STAT3, and B/Akt</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B44" ref-type="bibr">Liu et al., 2015</xref>)</td></tr><tr><td valign="top" rowspan="3" colspan="1">Breast cancer</td><td valign="top" rowspan="1" colspan="1">SKBR3</td><td valign="top" rowspan="1" colspan="1">Down-regulated HER2, decreased fatty acid synthase</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B36" ref-type="bibr">Lee et al., 2013</xref>)</td></tr><tr><td valign="top" rowspan="2" colspan="1">MDA-MB-231</td><td valign="top" rowspan="1" colspan="1">Suppressed proteasomal activity <italic>via</italic> increasing the levels of RGS4</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">Mu et al., 2012a</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Suppressed the LC3-II levels of this on ERK signaling when combination with paclitaxel</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B38" ref-type="bibr">Lee et al., 2018</xref>)</td></tr><tr><td valign="top" rowspan="3" colspan="1">Colorectal cancer</td><td valign="top" rowspan="1" colspan="1">HCT-116</td><td valign="top" rowspan="1" colspan="1">Inhibited the AKT/FOXO3a pathway <italic>via</italic> decreasing cyclinD1 and Bcl-XL, increased the expression of p21 and p27</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B57" ref-type="bibr">Park and Kim, 2018</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">HCT-116</td><td valign="top" rowspan="1" colspan="1">Inhibited activated NF-&#x0043a;B, TNF&#x003b1;, and activated LPS-induced NF-&#x0043a;B signaling pathway</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B92" ref-type="bibr">Yousef et al., 2018</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">HCT-116, COLO-205, and SW-620</td><td valign="top" rowspan="1" colspan="1">Inhibited of phosphorylated EGFR and HER2 expression, caused inhibition of related downstream kinases.</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B90" ref-type="bibr">Yousef et al., 2016a</xref>)</td></tr><tr><td valign="top" rowspan="2" colspan="1">Hepatocellular carcinoma</td><td valign="top" rowspan="2" colspan="1">HepG2</td><td valign="top" rowspan="1" colspan="1">Generated ROS, induced release of cytochrome <italic>c</italic>, and down-regulated EGFR protein</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B24" ref-type="bibr">Guo et al., 2013</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Disrupted HSP90/CDC37 interaction, degraded and inhibited phosphorylation of protein kinases in the Raf/MEK/ERK and PI3K/AKT/mTOR signaling pathways</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B80" ref-type="bibr">Wei et al., 2014</xref>)</td></tr><tr><td valign="top" rowspan="2" colspan="1">Pancreatic cancer</td><td valign="top" rowspan="1" colspan="1">BxPC-3, PANC-1, and AsPC-1</td><td valign="top" rowspan="1" colspan="1">Inhibited of the translocation and DNA-binding activity of NF-&#x003ba;B</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">Wang et al., 2012</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">MiaPaCa-2 and Panc-1</td><td valign="top" rowspan="1" colspan="1">Inhibited of hTERT <italic>via</italic> suppressing the transcription factors Sp1, c-Myc, and NF-&#x003ba;B</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B13" ref-type="bibr">Deeb et al., 2015</xref>)</td></tr><tr><td valign="top" rowspan="2" colspan="1">Glioma</td><td valign="top" rowspan="1" colspan="1">U87</td><td valign="top" rowspan="1" colspan="1">Activated of JNK through overproduction of ROS</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B97" ref-type="bibr">Zhao et al., 2016</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">U373</td><td valign="top" rowspan="1" colspan="1">Targeting AGO2 and PTPN1 expression <italic>via</italic> miR-542-5p</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B40" ref-type="bibr">Li et al., 2019</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Myeloma</td><td valign="top" rowspan="1" colspan="1">H929 and U266</td><td valign="top" rowspan="1" colspan="1">Both inhibited IKK phosphorylation of I&#x003ba;B and proteosome, causing unfolded protein response and suppressing NF-&#x003ba;B activity and cyclin D expression</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">Tiedemann et al., 2009</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Cervical cancer</td><td valign="top" rowspan="1" colspan="1">HeLa</td><td valign="top" rowspan="1" colspan="1">Activated ROS-dependent JNK, Bax, and PARP-1</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">Eum et al., 2011</xref>)</td></tr><tr><td valign="top" rowspan="2" colspan="1">Leukemia</td><td valign="top" rowspan="1" colspan="1">HL-60</td><td valign="top" rowspan="1" colspan="1">Interfered DNA synthesis</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B10" ref-type="bibr">Costa et al., 2008</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">KBM5 and KBM5-T3151</td><td valign="top" rowspan="1" colspan="1">Depleted Bcr-Abl, activated TAK1TIKK and IKKTI&#x003ba;B&#x003b1; in NF-&#x003ba;B signaling parallel but independent</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">Lu et al., 2010</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Ovarian carcinoma</td><td valign="top" rowspan="1" colspan="1">OVCAR-5, MDAH-2774, OVCAR-3, and SK-OV-3</td><td valign="top" rowspan="1" colspan="1">Inhibited prosurvival signaling proteins Akt, mTOR and NF-kB; inhibited NF-&#x003ba;B-regulated anti-apoptotic proteins Bcl-2, Bcl-xL, c-IAPl and survivin</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">Gao et al., 2014</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">Osteosarcoma</td><td valign="top" rowspan="1" colspan="1">MNNG and 143B</td><td valign="top" rowspan="1" colspan="1">Decreased expression of Akt, mTOR, and NF-&#x003ba;B</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B52" ref-type="bibr">Mori et al., 2017</xref>)</td></tr><tr><td valign="top" rowspan="2" colspan="1">Oral cancer</td><td valign="top" rowspan="1" colspan="1">KBv200</td><td valign="top" rowspan="1" colspan="1">Decreased P-gp through interrupt protein stability in MAPK and PI3K/Akt pathways</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B87" ref-type="bibr">Yan et al., 2017</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">CAL-27 and SCC-25</td><td valign="top" rowspan="1" colspan="1">G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">Wu et al., 2019</xref>)</td></tr><tr><td valign="top" rowspan="1" colspan="1">ESCC</td><td valign="top" rowspan="1" colspan="1">EC9706, EC109, and KYSE30</td><td valign="top" rowspan="1" colspan="1">Inhibited NF-&#x003ba;B pathway, synergistic effect with 5-FU</td><td valign="top" rowspan="1" colspan="1">(<xref rid="B74" ref-type="bibr">Tu et al., 2018</xref>)</td></tr></tbody></table><table-wrap-foot><p>ESCC, esophageal squamous cell carcinoma; ROS, reactive oxygen species.</p></table-wrap-foot></table-wrap><fig id="f2" position="float"><label>Figure 2</label><caption><p>Brief summary of anti-cancer mechanisms and activities of pristimerin.</p></caption><graphic xlink:href="fphar-10-00746-g002"/></fig></sec><sec sec-type="data-availability" id="s6"><title>Data Availability</title><p>All datasets analyzed for this study are included in the manuscript and the supplementary files.</p></sec><sec id="s7"><title>Author Contributions</title><p>JZ and HC conceived this review; JL and YY wrote the article. HS, YL, and CS revised the article.</p></sec><sec sec-type="funding-information" id="s8"><title>Funding</title><p>The work was supported by National Natural Science Foundation of China (81473320 and 81773888), Fund of Guangdong Science and Technology Department (2016A020226024), Fund of Guangzhou Science and Technology Program (201707010048), Fund of Guangdong Education Department (2015KTSCX112), and Fund of Construction of High Level Universities in Guangdong (Nanshan Scholars Program and Academic Backbone Program).</p></sec><sec id="s9"><title>Conflict of Interest Statement</title><p>HS was employed by Infinitus (China) Company Ltd.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alessia</surname><given-names>P.</given-names></name><name><surname>Gaetano</surname><given-names>P.</given-names></name><name><surname>Ugo</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Triterpenoids as new promising anticancer drugs</article-title>. <source>Anticancer Drugs</source>
<volume>20</volume>, <fpage>880</fpage>&#x02013;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1097/CAD.0b013e328330fd90</pub-id>
<pub-id pub-id-type="pmid">19745720</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andre</surname><given-names>P.</given-names></name><name><surname>Denis</surname><given-names>C.</given-names></name><name><surname>Soulas</surname><given-names>C.</given-names></name><name><surname>Bourbon-Caillet</surname><given-names>C.</given-names></name><name><surname>Lopez</surname><given-names>J.</given-names></name><name><surname>Arnoux</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells</article-title>. <source>Cell</source>
<volume>175</volume>, <fpage>1731</fpage>&#x02013;<lpage>1743</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.10.014</pub-id>
<pub-id pub-id-type="pmid">30503213</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>C. A.</given-names></name><name><surname>Tomita</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Fundamental mechanisms of telomerase action in yeasts and mammals: understanding telomeres and telomerase in cancer cells</article-title>. <source>Open Biol.</source>
<volume>7</volume>, <elocation-id>160338</elocation-id>. <pub-id pub-id-type="doi">10.1098/rsob.160338</pub-id>
<pub-id pub-id-type="pmid">28330934</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Avilla</surname><given-names>J.</given-names></name><name><surname>Teixid&#x000f2;</surname><given-names>A.</given-names></name><name><surname>Vel&#x000e1;zquez</surname><given-names>C.</given-names></name><name><surname>Alvarenga</surname><given-names>N.</given-names></name><name><surname>Ferro</surname><given-names>E.</given-names></name><name><surname>Canela</surname><given-names>R.</given-names></name></person-group> (<year>2000</year>). <article-title>Insecticidal activity of Maytenus Species (Celastraceae) Nortriterpene Quinone Methides against codling moth, Cydia pomonella (L). (Lepidoptera: Tortricidae)</article-title>. <source>J. Agric. Food Chem.</source>
<volume>48</volume>, <fpage>88</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1021/jf990008w</pub-id>
<pub-id pub-id-type="pmid">10637057</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brattain</surname><given-names>M. G.</given-names></name><name><surname>Howell</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>L. Z.</given-names></name><name><surname>Willson</surname><given-names>J. K.</given-names></name></person-group> (<year>1994</year>). <article-title>Growth factor balance and tumor progression</article-title>. <source>Curr. Opin. Oncol.</source>
<volume>6</volume>, <fpage>77</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1097/00001622-199401000-00011</pub-id>
<pub-id pub-id-type="pmid">8204695</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Byun</surname><given-names>J.-Y.</given-names></name><name><surname>Kim</surname><given-names>M.-J.</given-names></name><name><surname>Eum</surname><given-names>D.-Y.</given-names></name><name><surname>Yoon</surname><given-names>C.-H.</given-names></name><name><surname>Seo</surname><given-names>W.-D.</given-names></name><name><surname>Park</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Reactive oxygen species-dependent activation of Bax and Poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells</article-title>. <source>Mol. Pharmacol.</source>
<volume>76</volume>, <fpage>734</fpage>&#x02013;<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1124/mol.109.056259</pub-id>
<pub-id pub-id-type="pmid">19574249</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cevatemre</surname><given-names>B.</given-names></name><name><surname>Erk&#x00131;sa</surname><given-names>M.</given-names></name><name><surname>Aztopal</surname><given-names>N.</given-names></name><name><surname>Karakas</surname><given-names>D.</given-names></name><name><surname>Alper</surname><given-names>P.</given-names></name><name><surname>Tsimplouli</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts <italic>in vivo</italic> through apoptosis and an incomplete autopaghy in breast cancer</article-title>. <source>Pharmacol. Res.</source>
<volume>129</volume>, <fpage>500</fpage>&#x02013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.11.027</pub-id>
<pub-id pub-id-type="pmid">29197639</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaffer</surname><given-names>C. L.</given-names></name><name><surname>San Juan</surname><given-names>B. P.</given-names></name><name><surname>Lim</surname><given-names>E.</given-names></name><name><surname>Weinberg</surname><given-names>R. A.</given-names></name></person-group> (<year>2016</year>). <article-title>EMT, cell plasticity and metastasis</article-title>. <source>Cancer Metastasis Rev.</source>
<volume>35</volume>, <fpage>645</fpage>&#x02013;<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-016-9648-7</pub-id>
<pub-id pub-id-type="pmid">27878502</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chintharlapalli</surname><given-names>S.</given-names></name><name><surname>Papineni</surname><given-names>S.</given-names></name><name><surname>Ramaiah</surname><given-names>S. K.</given-names></name><name><surname>Safe</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors</article-title>. <source>Cancer Res.</source>
<volume>67</volume>, <fpage>2816</fpage>&#x02013;<lpage>2823</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3735</pub-id>
<pub-id pub-id-type="pmid">17363604</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Costa</surname><given-names>P. M. D.</given-names></name><name><surname>Ferreira</surname><given-names>P. M. P.</given-names></name><name><surname>Bolzani</surname><given-names>V. D. S.</given-names></name><name><surname>Furlan</surname><given-names>M.</given-names></name><name><surname>Corsino</surname><given-names>J.</given-names></name><name><surname>De Moraes</surname><given-names>M. O.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells</article-title>. <source>Toxicol. In Vitro</source>
<volume>22</volume>, <fpage>854</fpage>&#x02013;<lpage>863</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2008.01.003</pub-id>
<pub-id pub-id-type="pmid">18296021</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Brigolin</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Pindolia</surname><given-names>K. R.</given-names></name><name><surname>Gautam</surname><given-names>S. C.</given-names></name></person-group> (<year>2014</year>a). <article-title>Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves repression of telomerase through epigenetic pathways</article-title>. <source>J. Carcinog. Mutagen.</source>
<volume>5</volume>, <fpage>177</fpage>. <pub-id pub-id-type="doi">10.4172/2157-2518.1000177</pub-id>
<pub-id pub-id-type="pmid">25152840</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Pindolia</surname><given-names>K. R.</given-names></name><name><surname>Arbab</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Inhibition of cell proliferation and induction of apoptosis by oleanane triterpenoid (CDDO-Me) in pancreatic cancer cells is associated with the suppression of hTERT gene expression and its telomerase activity</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>422</volume>, <fpage>561</fpage>&#x02013;<lpage>567</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2012.05.024</pub-id>
<pub-id pub-id-type="pmid">22609405</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Pindolia</surname><given-names>K.</given-names></name><name><surname>Gautam</surname><given-names>S. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells</article-title>. <source>Oncol. Rep.</source>
<volume>34</volume>, <fpage>518</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.3892/or.2015.3989</pub-id>
<pub-id pub-id-type="pmid">25997419</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y. B.</given-names></name><name><surname>Pindolia</surname><given-names>K.</given-names></name><name><surname>Gautam</surname><given-names>S. C.</given-names></name></person-group> (<year>2014</year>b). <article-title>Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-kappaB/mTOR signaling proteins and anti-apoptotic Bcl-2</article-title>. <source>Int. J. Oncol.</source>
<volume>44</volume>, <fpage>1707</fpage>&#x02013;<lpage>1715</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2014.2325</pub-id>
<pub-id pub-id-type="pmid">24603988</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Dent</surname><given-names>M.a.R.</given-names></name><name><surname>Aranda-Anzaldo</surname><given-names>A.</given-names></name></person-group>
(<year>2019</year>). <article-title>Lessons we can learn from neurons to make cancer cells quiescent</article-title>. <source>J. Neurosci. Res.</source>
<pub-id pub-id-type="doi">10.1002/jnr.24428</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dewanjee</surname><given-names>S.</given-names></name><name><surname>Dua</surname><given-names>T. K.</given-names></name><name><surname>Bhattacharjee</surname><given-names>N.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Gangopadhyay</surname><given-names>M.</given-names></name><name><surname>Khanra</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Natural products as alternative choices for P-glycoprotein (P-gp) Inhibition</article-title>. <source>Molecules</source>
<volume>22</volume>, <fpage>871</fpage>. <pub-id pub-id-type="doi">10.3390/molecules22060871</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorstyn</surname><given-names>L.</given-names></name><name><surname>Akey</surname><given-names>C. W.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>New insights into apoptosome structure and function</article-title>. <source>Cell Death Differ.</source>
<volume>25</volume>, <fpage>1194</fpage>&#x02013;<lpage>1208</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-017-0025-z</pub-id>
<pub-id pub-id-type="pmid">29765111</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Efferth</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>Cancer combination therapies with artemisinin-type drugs</article-title>. <source>Biochem. Pharmacol.</source>
<volume>139</volume>, <fpage>56</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2017.03.019</pub-id>
<pub-id pub-id-type="pmid">28366726</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elmore</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Apoptosis: a review of programmed cell death</article-title>. <source>Toxicol. Pathol.</source>
<volume>35</volume>, <fpage>495</fpage>&#x02013;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1080/01926230701320337</pub-id>
<pub-id pub-id-type="pmid">17562483</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Estaquier</surname><given-names>J.</given-names></name><name><surname>Vallette</surname><given-names>F.</given-names></name><name><surname>Vayssiere</surname><given-names>J. L.</given-names></name><name><surname>Mignotte</surname><given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>The mitochondrial pathways of apoptosis</article-title>. <source>Adv. Exp. Med. Biol.</source>
<volume>942</volume>, <fpage>157</fpage>&#x02013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1007/978-94-007-2869-1_7</pub-id>
<pub-id pub-id-type="pmid">22399422</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eum</surname><given-names>D.-Y.</given-names></name><name><surname>Byun</surname><given-names>J.-Y.</given-names></name><name><surname>Yoon</surname><given-names>C.-H.</given-names></name><name><surname>Seo</surname><given-names>W.-D.</given-names></name><name><surname>Park</surname><given-names>K.-H.</given-names></name><name><surname>Lee</surname><given-names>J.-H.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction</article-title>. <source>Cell Death Dis.</source>
<volume>22</volume>, <fpage>763</fpage>&#x02013;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1097/CAD.0b013e328347181a</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>J. B.</given-names></name><name><surname>Sequin</surname><given-names>U.</given-names></name></person-group> (<year>1998</year>). <article-title>Novel quinone methides from Salacia kraussii with <italic>in vitro</italic> antimalarial activity</article-title>. <source>J. Nat. Prod.</source>
<volume>61</volume>, <fpage>718</fpage>&#x02013;<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1021/np9704157</pub-id>
<pub-id pub-id-type="pmid">9644053</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Arbab</surname><given-names>A. S.</given-names></name><name><surname>Gautam</surname><given-names>S. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-kappaB/mTOR signaling</article-title>. <source>J. Exp. Ther. Oncol.</source>
<volume>10</volume>, <fpage>275</fpage>&#x02013;<lpage>283</lpage>.<pub-id pub-id-type="pmid">25509983</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>Y. Y.</given-names></name><name><surname>Ma</surname><given-names>C. G.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction</article-title>. <source>J. BUON.</source>
<volume>18</volume>, <fpage>477</fpage>&#x02013;<lpage>485</lpage>.<pub-id pub-id-type="pmid">23818365</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group> (<year>2001</year>). <article-title>Molecular steps of death receptor and mitochondrial pathways of apoptosis</article-title>. <source>Life Sci.</source>
<volume>69</volume>, <fpage>2957</fpage>&#x02013;<lpage>2964</lpage>. <pub-id pub-id-type="doi">10.1016/S0024-3205(01)01404-7</pub-id>
<pub-id pub-id-type="pmid">11758823</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haroldo Jeller</surname><given-names>A.</given-names></name><name><surname>Helena Siqueira Silva</surname><given-names>D.</given-names></name><name><surname>Morais Li&#x000e3;o</surname><given-names>L.</given-names></name><name><surname>Da Silva Bolzani</surname><given-names>V.</given-names></name><name><surname>Furlan</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Antioxidant phenolic and quinonemethide triterpenes from Cheiloclinium cognatum</article-title>. <source>Phytochemistry</source>
<volume>65</volume>, <fpage>1977</fpage>&#x02013;<lpage>1982</lpage>. <pub-id pub-id-type="doi">10.1016/j.phytochem.2004.03.039</pub-id>
<pub-id pub-id-type="pmid">15280004</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ho</surname><given-names>J. W.</given-names></name><name><surname>Cheung</surname><given-names>M. W.</given-names></name></person-group> (<year>2014</year>). <article-title>Combination of phytochemicals as adjuvants for cancer therapy</article-title>. <source>Recent Pat. Anticancer Drug Discov.</source>
<volume>9</volume>, <fpage>297</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.2174/1574892809666140619154838</pub-id>
<pub-id pub-id-type="pmid">24942759</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>P.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Pristimerin inhibits prostate cancer bone metastasis by targeting PC-3 stem cell characteristics and VEGF-induced vasculogenesis of BM-EPCs</article-title>. <source>Cell. Physiol. Biochem.</source>
<volume>37</volume>, <fpage>253</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1159/000430350</pub-id>
<pub-id pub-id-type="pmid">26302893</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kale</surname><given-names>J.</given-names></name><name><surname>Osterlund</surname><given-names>E. J.</given-names></name><name><surname>Andrews</surname><given-names>D. W.</given-names></name></person-group> (<year>2018</year>). <article-title>BCL-2 family proteins: changing partners in the dance towards death</article-title>. <source>Cell Death Differ.</source>
<volume>25</volume>, <fpage>65</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2017.186</pub-id>
<pub-id pub-id-type="pmid">29149100</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ke</surname><given-names>B.</given-names></name><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>He</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy</article-title>. <source>Med. Res. Rev.</source>
<volume>36</volume>, <fpage>983</fpage>&#x02013;<lpage>1035</lpage>. <pub-id pub-id-type="doi">10.1002/med.21398</pub-id>
<pub-id pub-id-type="pmid">27357603</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Park</surname><given-names>G. M.</given-names></name><name><surname>Kim</surname><given-names>J.-K.</given-names></name></person-group> (<year>2013</year>). <article-title>Anti-inflammatory effect of pristimerin on lipopolysaccharide-induced inflammatory responses in murine macrophages</article-title>. <source>Arch. Pharm. Res.</source>
<volume>36</volume>, <fpage>495</fpage>&#x02013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-013-0054-1</pub-id>
<pub-id pub-id-type="pmid">23435916</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H.</given-names></name><name><surname>Tomari</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>RISC assembly: coordination between small RNAs and argonaute proteins</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1859</volume>, <fpage>71</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagrm.2015.08.007</pub-id>
<pub-id pub-id-type="pmid">26303205</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnamurthy</surname><given-names>N.</given-names></name><name><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors</article-title>. <source>Cancer Treat. Rev.</source>
<volume>62</volume>, <fpage>50</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctrv.2017.11.002</pub-id>
<pub-id pub-id-type="pmid">29169144</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>A. B.</given-names></name><name><surname>Shah</surname><given-names>R. C.</given-names></name></person-group> (<year>1954</year>). <article-title>Structure of pristimerin</article-title>. <source>Nature</source>
<volume>173</volume>, <fpage>1237</fpage>&#x02013;<lpage>1238</lpage>. <pub-id pub-id-type="doi">10.1038/1731237b0</pub-id>
<pub-id pub-id-type="pmid">13176424</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larsen</surname><given-names>H.</given-names></name><name><surname>Muz</surname><given-names>B.</given-names></name><name><surname>Khong</surname><given-names>T. L.</given-names></name><name><surname>Feldmann</surname><given-names>M.</given-names></name><name><surname>Paleolog</surname><given-names>E. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA</article-title>. <source>Arthritis Res. Ther.</source>
<volume>14</volume>, <fpage>R180</fpage>. <pub-id pub-id-type="doi">10.1186/ar3934</pub-id>
<pub-id pub-id-type="pmid">22866899</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. S.</given-names></name><name><surname>Yoon</surname><given-names>I. S.</given-names></name><name><surname>Lee</surname><given-names>M. S.</given-names></name><name><surname>Cha</surname><given-names>E. Y.</given-names></name><name><surname>Thuong</surname><given-names>P. T.</given-names></name><name><surname>Diep</surname><given-names>T. T.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells</article-title>. <source>Biol. Pharm. Bull.</source>
<volume>36</volume>, <fpage>316</fpage>&#x02013;<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b12-00685</pub-id>
<pub-id pub-id-type="pmid">23370361</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.-O.</given-names></name><name><surname>Kim</surname><given-names>J.-S.</given-names></name><name><surname>Lee</surname><given-names>M.-S.</given-names></name><name><surname>Lee</surname><given-names>H.-J.</given-names></name></person-group> (<year>2016</year>). <article-title>Anti-cancer effect of pristimerin by inhibition of HIF-1&#x003b1; involves the SPHK-1 pathway in hypoxic prostate cancer cells</article-title>. <source>BMC Cancer</source>
<volume>16</volume>, <fpage>701</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-016-2730-2</pub-id>
<pub-id pub-id-type="pmid">27581969</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Cha</surname><given-names>E.</given-names></name><name><surname>Sul</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation</article-title>. <source>Mol. Med. Rep.</source>
<volume>18</volume>, <fpage>4281</fpage>&#x02013;<lpage>4288</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2018.9488</pub-id>
<pub-id pub-id-type="pmid">30221728</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Kang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Tumor angiogenesis and anti-angiogenic gene therapy for cancer</article-title>. <source>Oncol. Lett.</source>
<volume>16</volume>, <fpage>687</fpage>&#x02013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.8733</pub-id>
<pub-id pub-id-type="pmid">29963134</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhen</surname><given-names>Y.</given-names></name><name><surname>Pang</surname><given-names>B.</given-names></name><name><surname>Yi</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>). <article-title>Pristimerin Inhibits Glioma Progression by Targeting AGO2 and PTPN1 Expression via miR-542-5p</article-title>. <source>Biosci. Rep.</source>
<volume>39</volume>. <pub-id pub-id-type="doi">10.1042/BSR20182389</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Euphorbia factor L2 induces apoptosis in A549 cells through the mitochondrial pathway</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>7</volume>, <fpage>59</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2016.06.008</pub-id>
<pub-id pub-id-type="pmid">28119809</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y. B.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Arbab</surname><given-names>A. S.</given-names></name><name><surname>Gautam</surname><given-names>S. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Pristimerin Induces Apoptosis in Prostate Cancer Cells by Down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal degradation pathway</article-title>. <source>J. Carcinog. Mutagen.</source>
<issue>Suppl 6</issue>, <fpage>5</fpage>. <pub-id pub-id-type="doi">10.4172/2157-2518.S6-005</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y. B.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Brigolin</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Shaw</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin</article-title>. <source>Int. J. Oncol.</source>
<volume>45</volume>, <fpage>1735</fpage>&#x02013;<lpage>1741</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2014.2561</pub-id>
<pub-id pub-id-type="pmid">25175770</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y. B.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Deeb</surname><given-names>D.</given-names></name><name><surname>Pindolia</surname><given-names>K.</given-names></name><name><surname>Gautam</surname><given-names>S. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Role of telomerase in anticancer activity of pristimerin in prostate cancer cells</article-title>. <source>J. Exp. Ther. Oncol.</source>
<volume>11</volume>, <fpage>41</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">26259389</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Livneh</surname><given-names>I.</given-names></name><name><surname>Cohen-Kaplan</surname><given-names>V.</given-names></name><name><surname>Cohen-Rosenzweig</surname><given-names>C.</given-names></name><name><surname>Avni</surname><given-names>N.</given-names></name><name><surname>Ciechanover</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death</article-title>. <source>Cell Res.</source>
<volume>26</volume>, <fpage>869</fpage>&#x02013;<lpage>885</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2016.86</pub-id>
<pub-id pub-id-type="pmid">27444871</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopez</surname><given-names>M. R.</given-names></name><name><surname>De Leon</surname><given-names>L.</given-names></name><name><surname>Moujir</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Antibacterial properties of phenolic triterpenoids against Staphylococcus epidermidis</article-title>. <source>Planta. Med.</source>
<volume>77</volume>, <fpage>726</fpage>&#x02013;<lpage>729</lpage>. <pub-id pub-id-type="doi">10.1055/s-0030-1250500</pub-id>
<pub-id pub-id-type="pmid">21049400</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Pan</surname></name><etal/></person-group> (<year>2010</year>). <article-title>Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-&#x003ba;B signaling and depleting Bcr-Abl</article-title>. <source>Mol. Cancer</source>
<volume>9</volume>, <fpage>112</fpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-9-112</pub-id>
<pub-id pub-id-type="pmid">20482842</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mabuchi</surname><given-names>S.</given-names></name><name><surname>Kuroda</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>R.</given-names></name><name><surname>Sasano</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer</article-title>. <source>Gynecol. Oncol.</source>
<volume>137</volume>, <fpage>173</fpage>&#x02013;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2015.02.003</pub-id>
<pub-id pub-id-type="pmid">25677064</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mayor</surname><given-names>T.</given-names></name><name><surname>Sharon</surname><given-names>M.</given-names></name><name><surname>Glickman</surname><given-names>M. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Tuning the proteasome to brighten the end of the journey</article-title>. <source>Am. J. Physiol., Cell Physiol.</source>
<volume>311</volume>, <fpage>C793</fpage>&#x02013;<lpage>C804</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00198.2016</pub-id>
<pub-id pub-id-type="pmid">27605452</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mena-Rejon</surname><given-names>G. J.</given-names></name><name><surname>Perez-Espadas</surname><given-names>A. R.</given-names></name><name><surname>Moo-Puc</surname><given-names>R. E.</given-names></name><name><surname>Cedillo-Rivera</surname><given-names>R.</given-names></name><name><surname>Bazzocchi</surname><given-names>I. L.</given-names></name><name><surname>Jimenez-Diaz</surname><given-names>I. A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Antigiardial activity of triterpenoids from root bark of Hippocratea excelsa</article-title>. <source>J. Nat. Prod.</source>
<volume>70</volume>, <fpage>863</fpage>&#x02013;<lpage>865</lpage>. <pub-id pub-id-type="doi">10.1021/np060559y</pub-id>
<pub-id pub-id-type="pmid">17385912</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N.</given-names></name><name><surname>Levine</surname><given-names>B.</given-names></name><name><surname>Cuervo</surname><given-names>A. M.</given-names></name><name><surname>Klionsky</surname><given-names>D. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Autophagy fights disease through cellular self-digestion</article-title>. <source>Nature</source>
<volume>451</volume>, <fpage>1069</fpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2004.11.046</pub-id>
<pub-id pub-id-type="pmid">18305538</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mori</surname><given-names>Y.</given-names></name><name><surname>Shirai</surname><given-names>T.</given-names></name><name><surname>Terauchi</surname><given-names>R.</given-names></name><name><surname>Tsuchida</surname><given-names>S.</given-names></name><name><surname>Mizoshiri</surname><given-names>N.</given-names></name><name><surname>Hayashi</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Antitumor effects of pristimerin on human osteosarcoma cells <italic>in vitro</italic> and in vivo</article-title>. <source>Onco. Targets Ther.</source>
<volume>10</volume>, <fpage>5703</fpage>&#x02013;<lpage>5710</lpage>. <pub-id pub-id-type="doi">10.2147/OTT.S150071</pub-id>
<pub-id pub-id-type="pmid">29238202</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mu</surname><given-names>X.-M.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>L.-X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.-R.</given-names></name><name><surname>Jiang</surname><given-names>Z.-Z.</given-names></name><etal/></person-group> (<year>2012</year>a). <article-title>Pristimerin Inhibits Breast Cancer Cell Migration by Up-regulating Regulator of G Protein Signaling 4 Expression</article-title>. <source>Asian Pac. J. Cancer Prev.</source>
<volume>13</volume>, <fpage>1097</fpage>&#x02013;<lpage>1104</lpage>. <pub-id pub-id-type="doi">10.7314/APJCP.2012.13.4.1097</pub-id>
<pub-id pub-id-type="pmid">22799288</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mu</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>b). <article-title>Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation</article-title>. <source>Molecules</source>
<volume>17</volume>, <fpage>6854</fpage>&#x02013;<lpage>6868</lpage>. <pub-id pub-id-type="doi">10.3390/molecules17066854</pub-id>
<pub-id pub-id-type="pmid">22669041</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murayama</surname><given-names>T.</given-names></name><name><surname>Eizuru</surname><given-names>Y.</given-names></name><name><surname>Yamada</surname><given-names>R.</given-names></name><name><surname>Sadanari</surname><given-names>H.</given-names></name><name><surname>Matsubara</surname><given-names>K.</given-names></name><name><surname>Rukung</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Anticytomegalovirus activity of pristimerin, a triterpenoid quinone methide isolated from Maytenus heterophylla (Eckl. &#x00026; Zeyh)</article-title>. <source>Antivir. Chem. Chemother.</source>
<volume>18</volume>, <fpage>133</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1177/095632020701800303</pub-id>
<pub-id pub-id-type="pmid">17626597</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Napetschnig</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Molecular basis of NF-kappaB signaling</article-title>. <source>Annu. Rev. Biophys.</source>
<volume>42</volume>, <fpage>443</fpage>&#x02013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biophys-083012-130338</pub-id>
<pub-id pub-id-type="pmid">23495970</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>J. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Pristimerin, a naturally occurring triterpenoid, attenuates tumorigenesis in experimental colitis-associated colon cancer</article-title>. <source>Phytomedicine</source>
<volume>42</volume>, <fpage>164</fpage>&#x02013;<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2018.03.033</pub-id>
<pub-id pub-id-type="pmid">29655682</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pecina-Slaus</surname><given-names>N.</given-names></name></person-group> (<year>2009</year>). <article-title>Genetic and molecular insights into apoptosis</article-title>. <source>Acta Med. Croatica</source>
<volume>63</volume>
<issue>Suppl 2</issue>, <fpage>13</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">19999541</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pedone</surname><given-names>E.</given-names></name><name><surname>Marucci</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Role of beta-catenin activation levels and fluctuations in controlling cell fate</article-title>. <source>Genes (Basel)</source>
<volume>10</volume>, <fpage>176</fpage>. <pub-id pub-id-type="doi">10.3390/genes10020176</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>S.</given-names></name><name><surname>Hang</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-kappaB pathways</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>6</volume>, <fpage>205</fpage>&#x02013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2016.02.002</pub-id>
<pub-id pub-id-type="pmid">27175331</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petho</surname><given-names>Z.</given-names></name><name><surname>Najder</surname><given-names>K.</given-names></name><name><surname>Bulk</surname><given-names>E.</given-names></name><name><surname>Schwab</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Mechanosensitive ion channels push cancer progression</article-title>. <source>Cell Calcium</source>
<volume>80</volume>, <fpage>79</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceca.2019.03.007</pub-id>
<pub-id pub-id-type="pmid">30991298</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>R. J.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Hypocrellin A-based photodynamic action induces apoptosis in A549 cells through ROS-mediated mitochondrial signaling pathway</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>9</volume>, <fpage>279</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2018.12.004</pub-id>
<pub-id pub-id-type="pmid">30972277</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ravanan</surname><given-names>P.</given-names></name><name><surname>Srikumar</surname><given-names>I. F.</given-names></name><name><surname>Talwar</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Autophagy: the spotlight for cellular stress responses</article-title>. <source>Life Sci.</source>
<volume>188</volume>, <fpage>53</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2017.08.029</pub-id>
<pub-id pub-id-type="pmid">28866100</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salminen</surname><given-names>A.</given-names></name><name><surname>Lehtonen</surname><given-names>M.</given-names></name><name><surname>Suuronen</surname><given-names>T.</given-names></name><name><surname>Kaarniranta</surname><given-names>K.</given-names></name><name><surname>Huuskonen</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Terpenoids: natural inhibitors of NF-&#x003ba;B signaling with anti-inflammatory and anticancer potential</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>65</volume>, <fpage>2979</fpage>&#x02013;<lpage>2999</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-008-8103-5</pub-id>
<pub-id pub-id-type="pmid">18516495</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>B. G.</given-names></name><name><surname>Bort</surname><given-names>A.</given-names></name><name><surname>Mateos-Gomez</surname><given-names>P. A.</given-names></name><name><surname>Rodriguez-Henche</surname><given-names>N.</given-names></name><name><surname>Diaz-Laviada</surname><given-names>I.</given-names></name></person-group> (<year>2019</year>). <article-title>Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase</article-title>. <source>Cancer Cell Int.</source>
<volume>19</volume>, <fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-019-0769-2</pub-id>
<pub-id pub-id-type="pmid">30899201</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Dean</surname><given-names>D. C.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Duan</surname><given-names>Z.</given-names></name></person-group> (<year>2019</year>). <article-title>Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: therapeutic potential of targeting CDKs signaling pathway</article-title>. <source>Hepatol. Res.</source>
<pub-id pub-id-type="doi">10.1111/hepr.13353</pub-id>
</mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>M.</given-names></name><name><surname>Wilkinson</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>ER homeostasis and autophagy</article-title>. <source>Essays Biochem.</source>
<volume>61</volume>, <fpage>625</fpage>&#x02013;<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1042/EBC20170092</pub-id>
<pub-id pub-id-type="pmid">29233873</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>ER-alpha36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>487</volume>, <fpage>625</fpage>&#x02013;<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2017.04.105</pub-id>
<pub-id pub-id-type="pmid">28435071</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W. Z.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>H. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis</article-title>. <source>J. Recept. Signal Transduct. Res.</source>
<volume>35</volume>, <fpage>600</fpage>&#x02013;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.3109/10799893.2015.1030412</pub-id>
<pub-id pub-id-type="pmid">26096166</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>W.-H.</given-names></name><name><surname>Bai</surname><given-names>S.-T.</given-names></name><name><surname>Tong</surname><given-names>L.</given-names></name><name><surname>Duan</surname><given-names>W.-J.</given-names></name><name><surname>Su</surname><given-names>J.-W.</given-names></name><name><surname>Chen</surname><given-names>J.-X.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Chemical constituents from Celastrus aculeatus Merr</article-title>. <source>Biochem. Syst. Ecol.</source>
<volume>54</volume>, <fpage>78</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.bse.2014.01.001</pub-id>
</mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C. Y.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>N. N.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2018</year>). <article-title>MicroRNA-497 accelerates apoptosis while inhibiting proliferation, migration, and invasion through negative regulation of the MAPK/ERK signaling pathway via RAF-1</article-title>. <source>J. Cell. Physiol.</source>
<volume>233</volume>, <fpage>6578</fpage>&#x02013;<lpage>6588</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.26272</pub-id>
<pub-id pub-id-type="pmid">29150931</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y. W.</given-names></name><name><surname>Lin</surname><given-names>Y. C.</given-names></name><name><surname>She</surname><given-names>Z. G.</given-names></name><name><surname>Lin</surname><given-names>M. T.</given-names></name><name><surname>Chen</surname><given-names>P. X.</given-names></name><name><surname>Zhang</surname><given-names>J. Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Anticancer activity and mechanism investigation of beauvericin isolated from secondary metabolites of the mangrove endophytic fungi</article-title>. <source>Anticancer Agents Med. Chem.</source>
<volume>15</volume> (<issue>2</issue>), <fpage>258</fpage>&#x02013;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.2174/1871520614666140825112255</pub-id>
<pub-id pub-id-type="pmid">25641103</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tiedemann</surname><given-names>R. E.</given-names></name><name><surname>Schmidt</surname><given-names>J.</given-names></name><name><surname>Keats</surname><given-names>J. J.</given-names></name><name><surname>Shi</surname><given-names>C. X.</given-names></name><name><surname>Zhu</surname><given-names>Y. X.</given-names></name><name><surname>Palmer</surname><given-names>S. E.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Blood</source>
<volume>113</volume>, <fpage>4027</fpage>&#x02013;<lpage>4037</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2008-09-179796</pub-id>
<pub-id pub-id-type="pmid">19096011</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>F.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Pristimerin targeting NF-&#x003ba;B pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells</article-title>. <source>Cell Biochem. Funct.</source>
<volume>36</volume>, <fpage>228</fpage>&#x02013;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1002/cbf.3335</pub-id>
<pub-id pub-id-type="pmid">29781107</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S.</given-names></name><name><surname>Weinberg</surname><given-names>R. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Tumor metastasis: molecular insights and evolving paradigms</article-title>. <source>Cell</source>
<volume>147</volume>, <fpage>275</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.09.024</pub-id>
<pub-id pub-id-type="pmid">22000009</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Shan</surname><given-names>X. B.</given-names></name><name><surname>Qiao</surname><given-names>Y. J.</given-names></name></person-group> (<year>2017</year>). <article-title>PDK2 promotes chondrogenic differentiation of mesenchymal stem cells by upregulation of Sox6 and activation of JNK/MAPK/ERK pathway</article-title>. <source>Braz. J. Med. Biol. Res.</source>
<volume>50</volume>, <elocation-id>e5988</elocation-id>. <pub-id pub-id-type="doi">10.1590/1414-431x20165988</pub-id>
<pub-id pub-id-type="pmid">28225870</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Dexmedetomidine protects against oxygen-glucose deprivation/reoxygenation injury-induced apoptosis via the p38 MAPK/ERK signalling pathway</article-title>. <source>J. Int. Med. Res.</source>
<volume>46</volume>, <fpage>675</fpage>&#x02013;<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1177/0300060517734460</pub-id>
<pub-id pub-id-type="pmid">29210287</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Feigon</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Structural biology of telomerase and its interaction at telomeres</article-title>. <source>Curr. Opin. Struct. Biol.</source>
<volume>47</volume>, <fpage>77</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2017.06.010</pub-id>
<pub-id pub-id-type="pmid">28732250</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Jia</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells</article-title>. <source>PLoS One</source>
<volume>7</volume>, <elocation-id>e43826</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0043826</pub-id>
<pub-id pub-id-type="pmid">22952775</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>C. K.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts</article-title>. <source>Oncotarget</source>
<volume>5</volume>, <fpage>5819</fpage>&#x02013;<lpage>5831</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2171</pub-id>
<pub-id pub-id-type="pmid">25051375</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Ai</surname><given-names>Z.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition</article-title>. <source>Oncol. Lett.</source>
<volume>17</volume>, <fpage>3017</fpage>&#x02013;<lpage>3025</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2019.9903</pub-id>
<pub-id pub-id-type="pmid">30854080</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Nie</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches</article-title>. <source>Cancer Lett.</source>
<volume>347</volume>, <fpage>159</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2014.03.013</pub-id>
<pub-id pub-id-type="pmid">24657660</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>Asiatic acid inhibits lung cancer cell growth in vitro and in vivo by destroying mitochondria</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>7</volume>, <fpage>65</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2016.04.003</pub-id>
<pub-id pub-id-type="pmid">28119810</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>I. M.</given-names></name></person-group> (<year>2014</year>). <article-title>NF-kappaB, an active player in human cancers</article-title>. <source>Cancer Immunol. Res.</source>
<volume>2</volume>, <fpage>823</fpage>&#x02013;<lpage>830</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0112</pub-id>
<pub-id pub-id-type="pmid">25187272</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Xing</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Ling</surname><given-names>M. T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Garlic-derived compound S-allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRP6/Wnt pathway</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>8</volume>, <fpage>575</fpage>&#x02013;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2017.10.003</pub-id>
<pub-id pub-id-type="pmid">30109182</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>G. E.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling</article-title>. <source>Oncol. Lett.</source>
<volume>11</volume>, <fpage>3111</fpage>&#x02013;<lpage>3116</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2016.4335</pub-id>
<pub-id pub-id-type="pmid">27123073</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.-Y.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>X.-Q.</given-names></name><name><surname>Wang</surname><given-names>X.-K.</given-names></name><name><surname>Chen</surname><given-names>Y.-F.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro</article-title>. <source>Oncol. Rep.</source>
<volume>37</volume>, <fpage>31</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3892/or.2016.5230</pub-id>
<pub-id pub-id-type="pmid">27840996</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y. Y.</given-names></name><name><surname>Bai</surname><given-names>J. P.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>J. Z.</given-names></name><name><surname>Ma</surname><given-names>C. G.</given-names></name></person-group> (<year>2013</year>). <article-title>The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction</article-title>. <source>Oncol. Lett.</source>
<volume>5</volume>, <fpage>242</fpage>&#x02013;<lpage>248</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2012.982</pub-id>
<pub-id pub-id-type="pmid">23255929</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Landis-Piwowar</surname><given-names>K. R.</given-names></name><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Yuan</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Reddy</surname><given-names>G. P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells</article-title>. <source>J. Cell. Biochem.</source>
<volume>103</volume>, <fpage>234</fpage>&#x02013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.21399</pub-id>
</mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yousef</surname><given-names>B. A.</given-names></name><name><surname>Guerram</surname><given-names>M.</given-names></name><name><surname>Hassan</surname><given-names>H. M.</given-names></name><name><surname>Hamdi</surname><given-names>A. M.</given-names></name><name><surname>Zhang</surname><given-names>L.-Y.</given-names></name><name><surname>Jiang</surname><given-names>Z.-Z.</given-names></name></person-group> (<year>2016</year>a). <article-title>Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins</article-title>. <source>Oncol. Rep.</source>
<volume>35</volume>, <fpage>1091</fpage>&#x02013;<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.3892/or.2015.4457</pub-id>
<pub-id pub-id-type="pmid">26718323</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yousef</surname><given-names>B. A.</given-names></name><name><surname>Hassan</surname><given-names>H. M.</given-names></name><name><surname>Guerram</surname><given-names>M.</given-names></name><name><surname>Hamdi</surname><given-names>A. M.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.-Y.</given-names></name><etal/></person-group> (<year>2016</year>b). <article-title>Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells</article-title>. <source>Biomed. Pharmacother.</source>
<volume>79</volume>, <fpage>112</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2016.02.003</pub-id>
<pub-id pub-id-type="pmid">27044819</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yousef</surname><given-names>B. A.</given-names></name><name><surname>Hassan</surname><given-names>H. M.</given-names></name><name><surname>Zhang</surname><given-names>L.-Y.</given-names></name><name><surname>Jiang</surname><given-names>Z.-Z.</given-names></name></person-group> (<year>2018</year>). <article-title>Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-&#x0043a;B signaling pathway in colorectal cancer cells</article-title>. <source>Phytomedicine</source>
<volume>40</volume>, <fpage>140</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2018.01.008</pub-id>
</mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yousef</surname><given-names>B. A.</given-names></name><name><surname>Hassan</surname><given-names>H. M.</given-names></name><name><surname>Zhang</surname><given-names>L. Y.</given-names></name><name><surname>Jiang</surname><given-names>Z. Z.</given-names></name></person-group> (<year>2017</year>). <article-title>Anticancer potential and molecular targets of pristimerin: a mini-review</article-title>. <source>Curr. Cancer Drug Targets</source>
<volume>17</volume>, <fpage>100</fpage>&#x02013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.2174/1568009616666160112105824</pub-id>
<pub-id pub-id-type="pmid">26758533</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. Y.</given-names></name><name><surname>Lin</surname><given-names>M. T.</given-names></name><name><surname>Tung</surname><given-names>H. Y.</given-names></name><name><surname>Tang</surname><given-names>S. L.</given-names></name><name><surname>Yi</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>Y. Z.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Bruceine D induces apoptosis in human chronic myeloid leukemia K562 cells via mitochondrial pathway</article-title>. <source>Am. J. Cancer Res.</source>
<volume>6</volume>, <fpage>819</fpage>.<pub-id pub-id-type="pmid">27186433</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. Y.</given-names></name><name><surname>Lin</surname><given-names>M. T.</given-names></name><name><surname>Zhou</surname><given-names>M. J.</given-names></name><name><surname>Yi</surname><given-names>T.</given-names></name><name><surname>Tang</surname><given-names>Y. N.</given-names></name><name><surname>Tang</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Combinational treatment of curcumin and quercetin against gastric cancer MGC-803 cells <italic>in vitro</italic></article-title>. <source>Molecules</source>
<volume>20</volume>, <fpage>11524</fpage>&#x02013;<lpage>11534</lpage>. <pub-id pub-id-type="doi">10.3390/molecules200611524</pub-id>
<pub-id pub-id-type="pmid">26111180</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Hui</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Pristimerin enhances the effect of cisplatin by inhibiting the miR23a/Akt/GSK3beta signaling pathway and suppressing autophagy in lung cancer cells</article-title>. <source>Int. J. Molec. Med.</source>
<volume>43</volume>, <fpage>1382</fpage>&#x02013;<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2019.4057</pub-id>
<pub-id pub-id-type="pmid">30664149</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Pristimerin triggers AIF-dependent programmed necrosis in glioma cells via activation of JNK</article-title>. <source>Cancer Lett.</source>
<volume>374</volume>, <fpage>136</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2016.01.055</pub-id>
<pub-id pub-id-type="pmid">26854718</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuo</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Inhibitory action of pristimerin on hypoxia-mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells</article-title>. <source>Oncol. Rep.</source>
<volume>33</volume>, <fpage>1388</fpage>&#x02013;<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.3892/or.2015.3708</pub-id>
<pub-id pub-id-type="pmid">25571882</pub-id></mixed-citation></ref></ref-list></back></article>